Eagle Pharmaceuticals Stock Price, News & Analysis (NASDAQ:EGRX)

$62.09 -0.47 (-0.75 %)
(As of 01/16/2018 02:52 AM ET)
Previous Close$62.56
Today's Range$61.51 - $64.29
52-Week Range$45.05 - $97.15
Volume319,808 shs
Average Volume214,067 shs
Market Capitalization$926.48 million
P/E Ratio10.00
Dividend YieldN/A
Beta1.24

About Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:EGRX
CUSIPN/A
Phone+1-201-3265300

Debt

Debt-to-Equity Ratio0.26%
Current Ratio5.30%
Quick Ratio5.15%

Price-To-Earnings

Trailing P/E Ratio9.99838969404187
Forward P/E Ratio27.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$189.48 million
Price / Sales4.89
Cash Flow$5.38 per share
Price / Cash11.54
Book Value$9.80 per share
Price / Book6.34

Profitability

Trailing EPS$6.21
Net Income$81.45 million
Net Margins36.95%
Return on Equity62.60%
Return on Assets44.24%

Miscellaneous

Employees77
Outstanding Shares14,920,000

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals declared that its board has approved a share repurchase plan on Thursday, August 10th 2017, which allows the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 13.3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.07 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.50. Eagle Pharmaceuticals had a net margin of 36.95% and a return on equity of 62.60%. View Eagle Pharmaceuticals' Earnings History.

Where is Eagle Pharmaceuticals' stock going? Where will Eagle Pharmaceuticals' stock price be in 2018?

3 analysts have issued twelve-month target prices for Eagle Pharmaceuticals' stock. Their forecasts range from $37.00 to $75.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $62.33 in the next year. View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (1/9/2018)
  • 2. Mizuho analysts commented, "We view both these programs as zeroes. On the call, mgmt. highlighted its balance sheet flexibility and we continue to believe that the company needs to buy its way out of its current pipeline predicament, ahead of Treanda generics in 2019 (and expect capitulation on further Ryanodex development only after this deal is announced). We summarize 3Q:17 performance in Exhibit 1. We will update our valuation after further digesting call details." (11/8/2017)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:

  • Michael Graves, Independent Chairman of the Board (Age 54)
  • Scott L. Tarriff, Chief Executive Officer, Independent Director (Age 57)
  • Pete A. Meyers, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer (Age 47)
  • David E. Riggs, Chief Financial Officer (Age 65)
  • Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer (Age 57)
  • Adrian J. Hepner M.D. Ph.D, Executive Vice President, Chief Medical Officer (Age 55)
  • Douglas L. Braunstein, Independent Director (Age 56)
  • Richard A. Edlin, Independent Director (Age 56)
  • Sander A. Flaum, Independent Director (Age 80)
  • Robert L. Glenning, Independent Director (Age 56)

How do I buy Eagle Pharmaceuticals stock?

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $62.09.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $926.48 million and generates $189.48 million in revenue each year. The specialty pharmaceutical company earns $81.45 million in net income (profit) each year or $6.21 on an earnings per share basis. Eagle Pharmaceuticals employs 77 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 Tice Blvd Ste 315, WOODCLIFF LAKE, NJ 07677-7637, United States. The specialty pharmaceutical company can be reached via phone at +1-201-3265300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (EGRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eagle Pharmaceuticals (NASDAQ:EGRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.332.332.502.50
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $62.33$62.33$72.50$91.50
Price Target Upside: 12.68% upside12.68% upside28.27% upside19.61% upside

Eagle Pharmaceuticals (NASDAQ:EGRX) Consensus Price Target History

Price Target History for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Royal Bank of CanadaReiterated RatingOutperform -> Outperform$81.00 -> $75.00N/AView Rating Details
11/8/2017MizuhoReiterated RatingSell$37.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$75.00N/AView Rating Details
11/2/2016William BlairBoost Price TargetOutperform$83.00 -> $97.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Eagle Pharmaceuticals (NASDAQ:EGRX) Earnings History and Estimates Chart

Earnings by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ EGRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017$0.57$1.07ViewN/AView Earnings Details
8/9/2017Q2 2017$0.51$0.33$52.52 million$50.10 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.44$1.42$70.10 million$76.80 millionViewListenView Earnings Details
3/1/2017Q416$2.24$3.52$86.13 million$81.10 millionViewListenView Earnings Details
11/9/2016Q316$0.71$0.73$41.04 million$37.80 millionViewListenView Earnings Details
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.53$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.59)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.56$1.31$3.41 million$36.30 millionViewListenView Earnings Details
2/17/2015Q4 2014($0.39)ViewN/AView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.90 million$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.39)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Eagle Pharmaceuticals (NASDAQ:EGRX) Earnings Estimates

Current Year EPS Consensus Estimate: $2.23 EPS
Next Year EPS Consensus Estimate: $3.94 EPS

Dividends

Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.50%
Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017Pete A MeyersCFOBuy350$55.45$19,407.50700View SEC Filing  
8/9/2017Douglas L BraunsteinDirectorBuy20,400$49.07$1,001,028.00View SEC Filing  
6/12/2017Pete A MeyersCFOBuy350$71.49$25,021.50350View SEC Filing  
5/19/2017David PernockInsiderBuy255$79.69$20,320.95966View SEC Filing  
5/16/2017David PernockInsiderBuy200$82.24$16,448.00711View SEC Filing  
4/25/2017Proquest Investments Iv, L.P.Major ShareholderSell54,180$88.38$4,788,428.40View SEC Filing  
4/3/2017Proquest Investments Iv, L.P.Major ShareholderSell91,332$83.09$7,588,775.88View SEC Filing  
3/29/2017Proquest Investments Iv, L.P.Major ShareholderSell106,468$83.01$8,837,908.68View SEC Filing  
3/28/2017Proquest Investments Iv, L.P.Major ShareholderSell6,182$83.02$513,229.64View SEC Filing  
3/27/2017Proquest Investments Iv, L.P.Major ShareholderSell39,431$83.00$3,272,773.00View SEC Filing  
3/23/2017Proquest Investments Iv, L.P.Major ShareholderSell1,200$83.05$99,660.00View SEC Filing  
3/23/2017Steven L KrillEVPSell14,125$81.07$1,145,113.755,023View SEC Filing  
3/22/2017Richard A EdlinDirectorBuy6,000$79.44$476,640.0029,400View SEC Filing  
3/21/2017David PernockInsiderBuy61$83.98$5,122.78511View SEC Filing  
3/20/2017Proquest Investments Iv, L.P.Major ShareholderSell100,000$82.06$8,206,000.00View SEC Filing  
3/9/2017David PernockInsiderBuy450$77.84$35,028.00450View SEC Filing  
1/4/2017Proquest Investments Iv, L.P.Major ShareholderSell65,114$85.16$5,545,108.24View SEC Filing  
12/13/2016Steven B RatoffDirectorSell10,000$75.01$750,100.0023,324View SEC Filing  
11/28/2016Sander A FlaumDirectorSell5,000$78.66$393,300.0011,374View SEC Filing  
11/11/2016Proquest Investments Iv, L.P.Major ShareholderSell34,486$85.15$2,936,482.90View SEC Filing  
11/9/2016Proquest Investments Iv, L.P.Major ShareholderSell153,830$79.29$12,197,180.70View SEC Filing  
11/7/2016Proquest Investments Iv, L.P.Major ShareholderSell5,030$75.39$379,211.70View SEC Filing  
11/4/2016Proquest Investments Iv, L.P.Major ShareholderSell245,770$71.02$17,454,585.40View SEC Filing  
9/30/2016Proquest Investments Iv, L.P.Major ShareholderSell22,100$70.06$1,548,326.00View SEC Filing  
9/29/2016Proquest Investments Iv, L.P.Major ShareholderSell77,900$70.04$5,456,116.00View SEC Filing  
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.951,369,946View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.001,000View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.801,420,491View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.2516,374View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.501,453,400View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.571,467,450View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.761,486,789View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.751,504,667View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eagle Pharmaceuticals (NASDAQ EGRX) News Headlines

Source:
DateHeadline
Eagle Pharmaceuticals (EGRX) Lowered to Hold at Zacks Investment ResearchEagle Pharmaceuticals (EGRX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 9 at 11:20 PM
Eagle Pharmaceuticals, Inc. to Present at 36th Annual J.P. Morgan Healthcare ConferenceEagle Pharmaceuticals, Inc. to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:30 AM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : December 28, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 1:15 PM
Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 1:15 PM
Eagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Rating of "Hold" from BrokeragesEagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 22 at 12:24 PM
Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : December 21, 2017Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : December 21, 2017
finance.yahoo.com - December 21 at 9:32 AM
Eagle Pharmaceuticals (EGRX) & Assembly Biosciences (ASMB) Financial ContrastEagle Pharmaceuticals (EGRX) & Assembly Biosciences (ASMB) Financial Contrast
www.americanbankingnews.com - December 18 at 9:34 AM
Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant - Business Wire (press release)Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant - Business Wire (press release)
www.businesswire.com - December 7 at 9:48 AM
Eagle Pharmaceuticals Commences Pivotal Study for FulvestrantEagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
finance.yahoo.com - December 7 at 9:48 AM
Eagle Pharmaceuticals (EGRX) Lifted to Buy at BidaskClubEagle Pharmaceuticals (EGRX) Lifted to Buy at BidaskClub
www.americanbankingnews.com - December 2 at 2:38 PM
Eagle Pharmaceuticals, Inc. (EGRX) Given Consensus Recommendation of "Hold" by AnalystsEagle Pharmaceuticals, Inc. (EGRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 27 at 1:00 PM
Eagle Pharmaceuticals, Inc. (EGRX) Given Average Rating of "Hold" by AnalystsEagle Pharmaceuticals, Inc. (EGRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 27 at 1:00 PM
Eagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Recommendation of "Hold" from BrokeragesEagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 27 at 12:58 PM
Eagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare ConferenceEagle Pharmaceuticals, Inc. to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 20 at 7:03 PM
Barron’s After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals PlungesBarron’s After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges
www.barrons.com - November 18 at 2:56 AM
Barrons After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals PlungesBarron's After Hours: Splunk Surges, 21st Century Fox Jumps, Eagle Pharmaceuticals Plunges
finance.yahoo.com - November 17 at 12:38 PM
FY2018 EPS Estimates for Eagle Pharmaceuticals, Inc. (EGRX) Raised by AnalystFY2018 EPS Estimates for Eagle Pharmaceuticals, Inc. (EGRX) Raised by Analyst
www.americanbankingnews.com - November 13 at 8:58 AM
Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017Eagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : November 10, 2017
finance.yahoo.com - November 10 at 7:09 PM
Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : November 9, 2017
finance.yahoo.com - November 10 at 11:48 AM
Eagle Pharmaceuticals, Inc. to Host Earnings CallEagle Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 1:43 AM
Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 ResultsEagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results
finance.yahoo.com - November 9 at 1:43 AM
Eagle Pharmaceuticals posts 3Q profitEagle Pharmaceuticals posts 3Q profit
finance.yahoo.com - November 9 at 1:43 AM
Edited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of EGRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 1:43 AM
Mizuho Reiterates Sell Rating for Eagle Pharmaceuticals, Inc. (EGRX)Mizuho Reiterates Sell Rating for Eagle Pharmaceuticals, Inc. (EGRX)
www.americanbankingnews.com - November 8 at 5:08 PM
Eagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare ConferenceEagle Pharmaceuticals, Inc. to Present at Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 8 at 5:47 AM
Eagle Pharmaceuticals, Inc. (EGRX) Receives Average Recommendation of "Hold" from AnalystsEagle Pharmaceuticals, Inc. (EGRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 2 at 2:33 PM
Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017 - Business Wire (press release)Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017 - Business Wire (press release)
www.businesswire.com - October 30 at 6:54 PM
Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017
finance.yahoo.com - October 30 at 6:54 PM
FDA To Rule On Elagolix In Q2, More Light From CELGs RADIANCE, TGTX On Watch - NasdaqFDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch - Nasdaq
www.nasdaq.com - October 30 at 3:31 AM
Eagle Pharmaceuticals (EGRX) Announces Tentative FDA Approval ... - StreetInsider.comEagle Pharmaceuticals (EGRX) Announces Tentative FDA Approval ... - StreetInsider.com
www.streetinsider.com - October 28 at 1:26 AM
Eagle Pharma gets tentative FDA approval for Lillys Alimta versionEagle Pharma gets tentative FDA approval for Lilly's Alimta version
finance.yahoo.com - October 27 at 8:23 PM
Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute - Business Wire (press release)Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute - Business Wire (press release)
www.businesswire.com - October 27 at 3:20 PM
Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-DiluteEagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute
finance.yahoo.com - October 27 at 3:20 PM
FDA tentatively approves Eagle Pharmas cancer drugFDA tentatively approves Eagle Pharma's cancer drug
finance.yahoo.com - October 27 at 3:20 PM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 24, 2017
finance.yahoo.com - October 24 at 9:22 PM
Q3 2017 EPS Estimates for Eagle Pharmaceuticals, Inc. Cut by Analyst (EGRX)Q3 2017 EPS Estimates for Eagle Pharmaceuticals, Inc. Cut by Analyst (EGRX)
www.americanbankingnews.com - October 19 at 7:54 AM
Brokers Issue Forecasts for Eagle Pharmaceuticals, Inc.s Q4 2017 Earnings (EGRX)Brokers Issue Forecasts for Eagle Pharmaceuticals, Inc.'s Q4 2017 Earnings (EGRX)
www.americanbankingnews.com - October 18 at 11:20 AM
Eagle Pharmaceuticals (EGRX) Reports New Patent for RYANODEX - StreetInsider.comEagle Pharmaceuticals (EGRX) Reports New Patent for RYANODEX - StreetInsider.com
www.streetinsider.com - October 17 at 11:59 PM
Eagle Pharmaceuticals Announces New Patent for RYANODEXEagle Pharmaceuticals Announces New Patent for RYANODEX
finance.yahoo.com - October 17 at 6:58 PM
Eagle Pharmaceuticals is Now Oversold - NasdaqEagle Pharmaceuticals is Now Oversold - Nasdaq
www.nasdaq.com - October 16 at 9:23 PM
3 Biotech Values in a Fully Valued Market3 Biotech Values in a Fully Valued Market
finance.yahoo.com - October 15 at 5:30 PM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:46 PM
Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017
finance.yahoo.com - October 11 at 7:46 PM
Contrasting Eagle Pharmaceuticals (EGRX) & The CompetitionContrasting Eagle Pharmaceuticals (EGRX) & The Competition
www.americanbankingnews.com - October 9 at 10:24 PM
Reviewing Supernus Pharmaceuticals (SUPN) & Eagle Pharmaceuticals (EGRX)Reviewing Supernus Pharmaceuticals (SUPN) & Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - October 6 at 6:24 AM
ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017ETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 10:58 AM
Analyzing Eagle Pharmaceuticals (EGRX) and Its CompetitorsAnalyzing Eagle Pharmaceuticals (EGRX) and Its Competitors
www.americanbankingnews.com - September 28 at 8:30 PM
Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - September 25 at 11:26 AM
Eagle Pharmaceuticals (EGRX) versus Its Rivals Head-To-Head SurveyEagle Pharmaceuticals (EGRX) versus Its Rivals Head-To-Head Survey
www.americanbankingnews.com - September 24 at 8:10 PM
Daily Technical Summary Reports on Generic Drugs Stocks ... - PR Newswire (press release)Daily Technical Summary Reports on Generic Drugs Stocks ... - PR Newswire (press release)
www.prnewswire.com - September 22 at 8:38 AM

SEC Filings

Eagle Pharmaceuticals (NASDAQ:EGRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eagle Pharmaceuticals (NASDAQ:EGRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eagle Pharmaceuticals (NASDAQ EGRX) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.